Studies

Fructo-oligosaccharides in active Crohn’s disease

Adalimumab in UC

Infliximab stop in CD

Tacrolimus in steroid dependent UC

Infliximab switch to adalimumab in CD

Secukinumab in mode-severe CD

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn’s Disease

Profermin is efficacious in patients with active ulcerative colitis–a randomized controlled trial

Mesalazine in UC once or twice daily

Infliximab in postoperative recurrence in CD